Natco Pharma Launches Semaglutide Generic Injection in India

Natco Pharma Limited has announced the launch of its generic Semaglutide injection in India, effective March 21, 2026. The launch coincides with the expiration of the patent for the original formulation. The product has received approval from the Central Drugs Standard Control Organisation (CDSCO) for manufacturing and marketing in India.

The Semaglutide injection will be available in multi-dose vials under the brand names SEMANATTM and SEMAFULLTM. The vials will be offered in strengths of 2mg/1.5ml, 4mg/3ml, and 8mg/3ml. The maximum retail price is set at INR 1,290 for the 2mg/1.5ml and 4mg/3ml vials, and INR 1,750 for the 8mg/3ml vial. Additionally, a pen device version is planned for release in April 2026, with pricing at INR 4,000, INR 4,200, and INR 4,500 for the respective strengths.

Natco is the first company to introduce generic Semaglutide in multi-dose vials in India. The company is also offering the product to third parties for co-marketing. The introduction of this generic formulation is positioned as a cost-effective alternative, being approximately 70% cheaper than the pen device and 90% cheaper than the innovator’s brand.

The Semaglutide injection is indicated for adults with insufficiently controlled type 2 diabetes mellitus, to be used as an adjunct to diet and exercise. The availability of this generic option is expected to enhance patient accessibility to GLP-1 therapy.

Natco Pharma Limited develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products. The company is a research and development-oriented entity, focusing on oncology and limited competition molecules in the US market. Natco operates nine manufacturing sites and two R&D facilities in India, with approvals from several leading regulatory authorities, serving over 50 global markets.